InvestorsHub Logo
Followers 120
Posts 20736
Boards Moderated 0
Alias Born 06/13/2011

Re: caddiedad post# 409030

Monday, 05/15/2023 7:04:53 PM

Monday, May 15, 2023 7:04:53 PM

Post# of 426372
Caddie ..I think you have convinced me to double my position .
My break even will now be around $1.60
How about you ?
I posted the other day that IMHO AMRN might be a spec buy at these levels .
I think N7 said he was buying

AMRN is trading at the value of their cash on hand plus the value of their inventory .
If this court decision does nothing else beyond having the generics clearly communicate what the drug is for ...see below from Hikma ...and making pharmacies pay attention ...its a win for AMRN

Hikma’s FDA-approved Icosapent Ethyl Capsule product is indicated for the following indication: as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Hikma’s product is not approved for any other indication for the reference listed drug VASCEPA®.



Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News